Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

   Completed · Phase 3 · Crohn Disease

   NCT03440385 · Celgene Corporation · 5 U.S. investigators

   $52,028research payments

2. Ultrasound Evaluation for Baxter VASCU-GUARD Vascular Patches Post-Endarterectomy and Complications Assessment

   Completed · Carotid Endarterectomy (CEA) Surgical Patients

   NCT07048067 · Baxter Healthcare · 1 U.S. investigator

   $51,960research payments

3. A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

   Recruiting · Phase 3 · Chronic Kidney Disease

   NCT03619850 · Azurity Pharmaceuticals, Inc. · 5 U.S. investigators

   $51,937research payments

4. 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

   Recruiting · Phase 1 · Brain Metastases

   NCT06048094 · Blue Earth Diagnostics · 1 U.S. investigator

   $51,665research payments

5. Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

   Completed · Phase 3 · Muscular Dystrophy, Duchenne

   NCT03179631 · Ptc Therapeutics, Inc. · 3 U.S. investigators

   $51,220research payments

6. A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

   Completed · Phase 1 · Renal Impairment

   NCT06397872 · Madrigal Pharmaceuticals · 2 U.S. investigators

   $50,899research payments

7. Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)

   Completed · Phase 3 · Allergic Fungal Rhinosinusitis

   NCT04684524 · Sanofi US Services Inc. · 6 U.S. investigators

   $50,756research payments

8. An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

   Recruiting · Early phase 1 · Biochemically Recurrent Prostate Carcinoma

   NCT06813898 · Blue Earth Diagnostics · 1 U.S. investigator

   $50,658research payments

9. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

   Recruiting · Phase 3 · Alzheimer's Disease

   NCT06976216 · E.r. Squibb & Sons, L.l.c. · 17 U.S. investigators

   $50,457research payments

10. First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

    Completed · Phase 1 · Plasma Cell Myeloma

    NCT04000282 · Sanofi US Services Inc. · 1 U.S. investigator

    $50,427research payments

11. A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Active, not recruiting · Phase 3 · Plasma Cell Myeloma

    NCT03319667 · Sanofi US Services Inc. · 3 U.S. investigators

    $50,143research payments

12. [Trial of device that is not approved or cleared by the U.S. FDA]

    Withheld

    NCT07014995 · AbbVie Inc. · 5 U.S. investigators

    $50,040research payments

13. A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

    Completed · Phase 2 · Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

    NCT03332017 · Beone Medicines Ltd. · 3 U.S. investigators

    $49,815research payments

14. A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

    Completed · Phase 2 · Immune Thrombocytopenia

    NCT03395210 · Sanofi US Services Inc. · 3 U.S. investigators

    $49,582research payments

15. DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

    Completed · Phase 2 · Adenocarcinoma Gastric Stage IV With Metastases

    NCT04014075 · Daiichi Sankyo Inc. · 3 U.S. investigators

    $49,448research payments

16. Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

    Terminated · Phase 2 · Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

    NCT04524689 · Sanofi US Services Inc. · 1 U.S. investigator

    $49,441research payments

17. Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

    Active, not recruiting · Not applicable · Aortic Aneurysm, Thoracic

    NCT02777593 · W. L. Gore & Associates, Inc. · 14 U.S. investigators

    $49,366research payments

18. Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

    Active, not recruiting · Phase 2 · Warm Autoimmune Hemolytic Anemia (wAIHA)

    NCT05002777 · Genzyme Corporation · 4 U.S. investigators

    $49,307research payments

19. Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

    Active, not recruiting · Phase 3 · Metastatic Non Small Cell Lung Cancer

    NCT04685135 · Mirati Therapeutics, Inc. · 5 U.S. investigators

    $49,266research payments

20. A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT06028425 · Eli Lilly and Company · 1 U.S. investigator

    $49,051research payments

21. Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

    Active, not recruiting · Phase 3 · Superficial Basal Cell Carcinoma

    NCT03573401 · Biofrontera Inc. · 16 U.S. investigators

    $48,739research payments

22. A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

    Recruiting · Alagille Syndrome

    NCT06850038 · Ipsen Pharma Sas · 4 U.S. investigators

    $48,214research payments

23. Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

    Completed · Phase 4 · Septic Shock

    NCT05824767 · La Jolla Pharmaceutical Company · 1 U.S. investigator

    $48,200research payments

24. A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

    Terminated · Phase 1 · Acute Myeloid Leukaemia

    NCT05712278 · Sanofi US Services Inc. · 1 U.S. investigator

    $48,186research payments

25. A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

    Recruiting · Phase 3 · Endometrial Cancer

    NCT07022483 · Daiichi Sankyo Inc. · 2 U.S. investigators

    $47,300research payments

26. A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

    Recruiting · Phase 1 · Schizophrenia

    NCT07061288 · E.r. Squibb & Sons, L.l.c. · 6 U.S. investigators

    $46,977research payments

27. Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

    Completed · Phase 3 · Glaucoma, Open-Angle

    NCT02507687 · AbbVie Inc. · 3 U.S. investigators

    $46,476research payments

28. A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

    Terminated · Phase 3 · Breast Neoplasms

    NCT04752332 · Eli Lilly and Company · 11 U.S. investigators

    $46,374research payments

29. SIRT With Tremelimumab and Durvalumab for Resectable HCC

    Active, not recruiting · Phase 1 · Resectable Hepatocellular Carcinoma

    NCT05701488 · Sirtex Medical Inc · 1 U.S. investigator

    $46,189research payments

30. A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

    Active, not recruiting · Phase 2 · Non-Transfusion Dependent Beta-Thalassemia (NTDT)

    NCT06421636 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $46,125research payments

31. Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

    Recruiting · Not applicable · Heart Failure - NYHA II - IV

    NCT07069738 · Boston Scientific Corporation · 3 U.S. investigators

    $46,016research payments

32. Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

    Recruiting · Prostate Cancer (Adenocarcinoma)

    NCT06862856 · Blue Earth Diagnostics · 1 U.S. investigator

    $45,875research payments

33. Trima Non-DEHP Leukoreduced Red Blood Cell In Vivo Recovery Study

    Completed · Not applicable · Device Validation of In-vivo Performance

    NCT06602804 · Terumo Bct, Inc. · 0 U.S. investigators

    $45,712research payments

34. Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

    Status unknown · Phase 3 · Prostate Cancer

    NCT05799248 · Blue Earth Diagnostics · 1 U.S. investigator

    $45,592research payments

35. High-flow Nasal Oxygen Therapy for Advanced Endoscopy in High-risk Patients.

    Completed · Not applicable · Hypoxemia During Surgery

    NCT06610461 · Fisher & Paykel Healthcare Limited · 1 U.S. investigator

    $45,500research payments

36. Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

    Enrolling by invitation · Phase 3 · Polyneuropathy, Inflammatory Demyelinating, Chronic

    NCT06859099 · Sanofi US Services Inc. · 2 U.S. investigators

    $45,420research payments

37. Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

    Active, not recruiting · Not applicable · Aortic Aneurysm, Abdominal

    NCT02489539 · W. L. Gore & Associates, Inc. · 20 U.S. investigators

    $45,322research payments

38. A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

    Terminated · Phase 4 · Primary Open Angle Glaucoma

    NCT06407973 · Sight Sciences, Inc. · 12 U.S. investigators

    $45,215research payments

39. A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    Active, not recruiting · Phase 3 · Non-Small Cell Lung Cancer

    NCT04194944 · Eli Lilly and Company · 0 U.S. investigators

    $45,118research payments

40. A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

    Recruiting · Hereditary Angioedemas

    NCT07001280 · Csl Behring · 2 U.S. investigators

    $44,480research payments

41. Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

    Active, not recruiting · Multiple Myeloma

    NCT01838512 · E.r. Squibb & Sons, L.l.c. · 11 U.S. investigators

    $44,274research payments

42. A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

    Terminated · Phase 3 · Immunocompromised

    NCT05074433 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $43,922research payments

43. MED-EL Remote Care Multi-Center Feasibility Study

    Completed · Not applicable · Hearing Loss, Sensorineural

    NCT05973669 · Med-el Corporation · 1 U.S. investigator

    $43,861research payments

44. A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

    Recruiting · Phase 2 · Carcinoma, Non-Small-Cell Lung

    NCT06855771 · E.r. Squibb & Sons, L.l.c. · 26 U.S. investigators

    $43,736research payments

45. Success in Comaneci-assist Coils Embolization Surveillance Study (SUCCESS)

    Completed · Intracranial Aneurysm

    NCT04518670 · Rapid Medical Ltd · 1 U.S. investigator

    $43,534research payments

46. A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

    Recruiting · Phase 2 · Small Cell Lung Cancer

    NCT07155174 · AbbVie Inc. · 2 U.S. investigators

    $43,456research payments

47. Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

    Completed · Phase 3 · Atopic Dermatitis

    NCT03569293 · AbbVie Inc. · 15 U.S. investigators

    $43,376research payments

48. High Flow Nasal Cannula Compared to Standard Oxygen for Endoscopic Ultrasound

    Active, not recruiting · Not applicable · Endoscopic Ultrasound

    NCT06704867 · Fisher & Paykel Healthcare Limited · 1 U.S. investigator

    $43,265research payments

49. A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Active, not recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT05023980 · Eli Lilly and Company · 10 U.S. investigators

    $43,160research payments

50. A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

    Completed · Phase 2 · Crohn's Disease (CD)

    NCT02782663 · AbbVie Inc. · 11 U.S. investigators

    $42,822research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.